Wednesday’s Midday Stock Update: American Green Inc (ERBB), ImmunoCellular Therapeutics (IMUC), Organovo Holdings (ONVO), Frontier Communications Corporation (FTR), Cypress Semicon (CY)

By Carrie Williams

So far Wednesday, May 29, NASDAQ is down -1.03% and the S&P is down -0.94%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBBResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Organovo Holdings (ONVOResearch Report), Frontier Communications Corporation (FTRResearch Report) and Cypress Semicon (CYResearch Report).

American Green Inc is up 50% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

ImmunoCellular Therapeutics is up 17.5% in midday trading to $0.02. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Organovo Holdings is down -14.6% in midday trading to $0.41. Shares opened today at $0.48. The company has a 52-week low of $0.37 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.50, marking a 212.50% potential upside from current levels. In a report issued on May 24, H.C. Wainwright analyst Ed Arce maintained a Buy rating on ONVO, with a price target of $1.50, which implies an upside of 213% from current levels. Separately, on May 23, Jones Trading’s Matthew Cross downgraded the stock to Hold . In the last 30 days, insiders have sold $40.9K worth of ONVO shares.

See today’s analyst top recommended stocks >>

Frontier Communications Corporation is down -13.63% in midday trading to $1.87. Shares opened today at $2.17. The company has a 52-week low of $1.66 and a 52-week high of $0.00. In the last 30 days, insiders have sold $26.2K worth of FTR shares.

See today’s analyst top recommended stocks >>

Cypress Semicon is up 12.83% in midday trading to $17.32. Shares opened today at $15.35. The company has a 52-week low of $11.75 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $19.25, marking a 25.41% potential upside from current levels. In a report issued on May 17, Susquehanna analyst Christopher Rolland reiterated a Buy rating on CY, with a price target of $20, which implies an upside of 30% from current levels. In the last 30 days, insiders purchased $184.8K worth of CY shares.

Trending Stocks Based on Insider Activity >>